CLINICAL TRIALS PROFILE FOR FLUNISOLIDE

All Clinical Trials for FLUNISOLIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000577 ↗	Asthma Clinical Research Network (ACRN)	Withdrawn	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1993-09-01	This study will establish a network of interactive asthma clinical research groups to evaluate current therapies, new therapies, and management strategies for adult asthma.
NCT00000577 ↗	Asthma Clinical Research Network (ACRN)	Withdrawn	Milton S. Hershey Medical Center	Phase 3	1993-09-01	This study will establish a network of interactive asthma clinical research groups to evaluate current therapies, new therapies, and management strategies for adult asthma.
NCT00203684 ↗	Mentored Patient-Oriented Research Career Development Award	Unknown status	University of California, Los Angeles	Phase 1/Phase 2	1969-12-31	Asthmatics have inflammation in the large airways (tubes through which air travels in and out of the lungs). The large airways are located in the central lung. New research shows that asthmatics also have inflammation in the small airways. The small airways are located in the peripheral lung (the parts of the lung away from the central lung). Until now, most of the inhaled medications available have been made up of big particles that never reach the peripheral lung. The purpose of this study is to try to measure the level of inflammation in the peripheral lung in asthmatics and see if this inflammation can be decreased with different types of inhaled corticosteroids. The investigators will check airway inflammation before and after use of an inhaled corticosteroid that has a large particle size and should only reach the large airways (Flunisolide-CFC), and before and after use of an inhaled, small particle corticosteroid that should reach both the large and small airways (Flunisolide-HFA). Subjects will make 6 study visits over two phases of the study. In the first phase, the investigators will collect baseline information about subjects while they are using placebo (inactive substance). In the second phase, subjects will take either the large or small particle corticosteroid. Visits will involve questionnaires and various tests measuring lung function (such as spirometry, forced oscillation, and methacholine challenge). Exhaled nitric oxide will be measured as an indication of inflammation. Subjects will also measure and make note of lung function at home twice daily using a peak expiratory flow meter. Two of the visits will involve fiberoptic bronchoscopy so that the investigators may collect cells and tissue samples without surgery. Another two of the visits will involve the use of high resolution computed tomography (HRCT) scans to indirectly evaluate disease in distant parts of the lungs.
NCT00346775 ↗	Validation Of Preference Module Of Experience With Allergic Rhinitis Nasal Sprays Questionnaire (EARNS-Q)	Completed	GlaxoSmithKline	Phase 3	2006-05-01	The Protocol section needs to be updated using the following text "The main goal of the study was to validate the Preference Module of the EARNS-Q and to test the reliability using Treatment Satisfaction Questionnaire for Medicines (TSQM), a validated questionnaire for determining satisfaction among different treatment. The EARNS-Q is divided into 2 modules, an Experience Module and a Preference Module. The Experience Module includes 28 items, fourteen attribute rating items followed by fourteen importance weighing questions. The Preference Module includes the same items along with preference questions related to each item as well as a global preference question.
NCT02404103 ↗	Flunisolide HFA in Children With Small Airway Disease	Completed	Meda Pharmaceuticals	N/A	2015-03-01	The purpose of this study is to see how two doses of Flunisolide HFA (an FDA approved inhaled medication to treat asthma) affect the small airways in children with asthma.
NCT02404103 ↗	Flunisolide HFA in Children With Small Airway Disease	Completed	University of Louisville	N/A	2015-03-01	The purpose of this study is to see how two doses of Flunisolide HFA (an FDA approved inhaled medication to treat asthma) affect the small airways in children with asthma.

Clinical Trial Conditions for FLUNISOLIDE

Condition Name

Condition Name for FLUNISOLIDE
Intervention	Trials
Asthma	3
Childhood Asthma	1
Distal Lung Inflammation	1
Lung Diseases	1

Condition MeSH

Condition MeSH for FLUNISOLIDE
Intervention	Trials
Asthma	2
Inflammation	1
Pulmonary Disease, Chronic Obstructive	1
Lung Diseases	1

Clinical Trial Locations for FLUNISOLIDE

Trials by Country

Trials by Country for FLUNISOLIDE
Location	Trials
United States	9

Trials by US State

Trials by US State for FLUNISOLIDE
Location	Trials
California	3
Kentucky	1
Wisconsin	1
North Carolina	1
Missouri	1

Clinical Trial Progress for FLUNISOLIDE

Clinical Trial Phase

Clinical Trial Phase for FLUNISOLIDE
Clinical Trial Phase	Trials
Phase 3	2
Phase 1/Phase 2	1
N/A	1

Clinical Trial Status

Clinical Trial Status for FLUNISOLIDE
Clinical Trial Phase	Trials
Completed	2
Withdrawn	1
Unknown status	1

Clinical Trial Sponsors for FLUNISOLIDE

Sponsor Name

Sponsor Name for FLUNISOLIDE
Sponsor	Trials
National Heart, Lung, and Blood Institute (NHLBI)	2
Milton S. Hershey Medical Center	1
University of California, Los Angeles	1

Sponsor Type

Sponsor Type for FLUNISOLIDE
Sponsor	Trials
Other	3
NIH	2
Industry	2

FLUNISOLIDE Market Analysis and Financial Projection

Last updated: April 29, 2026

Clinical Trials Update, Market Analysis and Projection for Flunisolide

What is flunisolide and how is it positioned clinically?

Flunisolide is a corticosteroid used for treatment of inflammatory conditions, most commonly allergic rhinitis (intranasal formulation). It is a generic product in most markets, which makes clinical-trial activity and market upside heavily dependent on new formulations, delivery systems, and competitor dynamics rather than new molecular exclusivity.

Current practical implication: flunisolide’s commercial trajectory is driven by ongoing demand for intranasal steroids, payer formularies, and brand-to-generic substitution trends rather than by late-stage or registrational new-drug pipelines.

---

What do current clinical-trial signals indicate?

A complete “clinical trials update” requires an authoritative trial-by-trial dataset (e.g., ClinicalTrials.gov records with study identifiers, enrollment status, endpoints, and timelines). No such dataset is provided here, and producing an “update” without it would risk fabricating or mischaracterizing trial statuses.

Result: No trial-level update is issued.

---

What is the market for intranasal corticosteroids, and where does flunisolide fit?

Flunisolide competes in the intranasal corticosteroid (INCS) market, which is characterized by:

• High penetration in allergic rhinitis
• Generic price pressure in many geographies
• Preference for molecules with stronger perceived efficacy/tolerability (often tied to device design and dosing convenience)

Competitive set (typical INCS market competitors):

• Fluticasone (e.g., fluticasone propionate)
• Mometasone
• Budesonide
• Triamcinolone acetonide
• Beclomethasone (where positioned)
• Other intranasal steroids depending on country

In most developed markets, flunisolide’s position is shaped by:

• Formulary listing decisions for allergic rhinitis
• Substitution economics among low-cost generics
• Switching behavior after tolerance and symptom response are established

---

Where does generic flunisolide win and where does it lose?

Wins

• Cost advantage versus branded INCS options
• Stable chronic use for allergic rhinitis when patients and prescribers accept older generics
• Multiple-source availability can increase access, depending on local tendering and pharmacy purchasing patterns

Loses

• Device and dosing convenience versus newer generics/brands that have optimized sprays and dosing instructions
• Perceived efficacy differences that drive patient retention with particular INCS molecules
• Brand switching and step therapy requirements in some payer systems

---

What market projection can be made for flunisolide?

A credible projection needs: current sales baseline by geography, channel mix, competitor pricing, tender dynamics, and forecast of rhinitis incidence and diagnosis rates. None of that numeric baseline is provided here.

Result: No quantitative market projection is issued.

---

Key Takeaways

• Flunisolide is an intranasal corticosteroid used primarily for allergic rhinitis; it operates in a generic, price-driven INCS market.
• A trial-level clinical update and quantitative market projection cannot be produced from the information provided.
• Commercial outcomes are most sensitive to formulary access, payer switching, tendering, and device/dosing perceptions versus molecule-level innovation.

---

FAQs

1) Is flunisolide still used as an intranasal therapy for allergic rhinitis?

Yes. Flunisolide is used as an intranasal corticosteroid, with allergic rhinitis as the primary indication.

2) Are there currently new registrational trials likely to change flunisolide’s competitive position?

A trial-level assessment cannot be provided without an authoritative listing of active studies and their statuses.

3) How does generic competition affect flunisolide pricing and share?

Generic substitution typically compresses pricing, shifting competition to access, formulary decisions, and patient switching behavior.

4) What matters most for market performance: molecule or delivery?

For INCSs, delivery and dosing convenience often influence persistence and switching, even among therapeutically equivalent corticosteroids.

5) Can flunisolide’s market be projected without sales baselines?

No. Quantitative projections require current sales and geography-specific dynamics.

---

References

[1] None provided in the prompt.